Back to Investors
Investment Case
A diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology Manufacturers, Uniphar represents a strong combination of scale, growth and profitability.
In 2020, the Group generated revenue of €1.8 billion, gross profit of €217.3 million and EBITDA of €66.7 million. With a workforce of more than 2,600, the Group is active in Ireland, UK, Benelux, Nordics and USA.
Full Year 2020 Results
FY 2020 Key Stats
€66.7m
EBITDA
6.7%
Organic GP Growth YoY
18.9%
ROCE 2020
12.6c
Adjusted EPS
Group Highlights
€217.3m
2020 GP
Employees
Partnering with 7 of the top 10 pharma companies
and 7 of the top 10 medical device companies
